Jacob P. Waletzky Memorial Lecture Experience-Dependent Alterations in the Function of Brain Reward...

Preview:

Citation preview

Jacob P. Waletzky Memorial LectureJacob P. Waletzky Memorial Lecture

Experience-Dependent Alterations inExperience-Dependent Alterations in the Function of Brain Reward Systems:the Function of Brain Reward Systems:

The Role of CREBThe Role of CREB

William A. Carlezon, Jr., Ph.D.Behavioral Genetics Laboratory

Department of PsychiatryHarvard Medical School

McLean Hospital

Addiction and Depressive DisordersAddiction and Depressive Disorders

• • High rates of co-morbidity in both men and womenHigh rates of co-morbidity in both men and women (Kessler et al., 1997).(Kessler et al., 1997).

• • Causal relationships can be difficult to establish.Causal relationships can be difficult to establish.

• • Addictive behaviors and depressive disorders haveAddictive behaviors and depressive disorders have common triggers (e.g., stress).common triggers (e.g., stress).

• • Studies of addiction may give us insights on depressive Studies of addiction may give us insights on depressive disorders, and vice-versa.disorders, and vice-versa.

Working Hypothesis

Addiction and Depressive DisordersInvolve Brain Reward Systems

Mood in Rodents?

Sad

Happy

Worried

Hopeless Grumpy

Listless

Mood in Rodents?

Sad

GrumpyHappy

Anhedonia

Reward Dysphoria

WorriedAnxiety

HopelessDespair

ListlessHypoactivity

Mood in RodentsMood in Rodents

• • rewardreward (feelings of pleasure) (feelings of pleasure)

• • anhedoniaanhedonia ( (reduced ability to experience rewarding ability to experience rewarding things as rewarding)things as rewarding)

• • dysphoriadysphoria (feelings of discomfort) (feelings of discomfort)

• • despairdespair (feelings of giving up) (feelings of giving up)

• • anxiety anxiety (feelings of apprehension, fear)(feelings of apprehension, fear)

• • hypoactivityhypoactivity (less active than normal) (less active than normal)

Overview

1. CREB

2. Functional role of CREB in the NAc

3. CREB and dynorphin

4. Kappa antagonists and agonists

Overview

1. CREB

2. Functional role of CREB in the NAc

3. CREB and dynorphin

4. Kappa antagonists and agonists

CREB (cAMP Response Element Binding Protein)

AMPA/GluR1Rs NMDARs

Gs Gi/o

G protein-coupled receptors

Ca2+

PKA

ATPcAMP

CaM

MAPK

RSK

CaMKIV

CREB

CREB

P

P

alteredgeneexpression

CREB

L-type Ca2+channels

TrkB

Neurotrophinreceptors

adenylate cyclase

Gq

PLC

CaMKII

PDE

TH BDNF

Dynorphin

Fos CRF

Addictive Drugs Regulate CREB in the NAc

CREB phosphorylation

Turgeon et al., 1997

Drug Regulation of CREB

Are there behavioral correlates of CREBactivity in the NAc?

• Drug tolerance?

• Drug sensitization?

CREB

NAc VTA

Elevation of CREB with Engineered Viruses

Elevation of CREB with Engineered Viruses

CREB

NAc VTA

Blockade of CREB Function By Overexpressionof mCREB with Engineered Viruses

mCREB

NAc VTA

pHSV PrpUC

cDNA (e.g. CREB, mCREB, LacZ)

HSV-1c Region

pBR 322

aHSV-1

packagingsite

SV-40 polyadenylation

site

Amp

Col E1ori

oris IE 4/5 Promoter

(Neve Lab)

Gene Transfer Using Viral Vectors

Increased Protein Expression Minimal Damage

Overview

1. CREB

2. Functional role of CREB in the NAc

3. CREB and dynorphin

4. Kappa antagonists and agonists

Measurement of Drug Reward (and Aversion)

Effect of CREB Over Cocaine Doses

Ch

ang

e i

n T

ime

Sp

en

t in

Dru

g S

ide

(sec

)

Dysphoria

Anhedonia

Carlezon et al., 1998

Intracranial Self-Stimulation (ICSS)in mCREB transgenic mice

ICSS Thresholds

100%

Drugs of AbuseDrugs of Abuse(amphetamine, cocaine, opiates,

PCP, nicotine)

Aversive/ProdepressantsAversive/Prodepressants(drug withdrawal, lithium,

neuroleptics)

Intracranial Self-Stimulation (ICSS)in mCREB transgenic mice

.

Dose Cocaine (mg/kg, IP)

0.0 1.25 2.50.63 5.0 100

20

40

60

80

100

120 WT

* *** **

**

^^

mCREB

Thresholds%

Ba

se

line

Th

res

ho

lda

Forced Swim Test (FST)

SwimmingSwimming Immobile

Elevated CREB Increases Immobility in the FSTT

ime

(se

c)

Be

am

Bre

aks

(1

hr)

Latency to Immobility Locomotor Activity

HSV-mCREB

HSV-LacZ

HSV-CREB

Vehicle

CREB-On = More Depressive-like SignsCREB-On = More Depressive-like Signs

CREB-Off = Fewer Depressive-like SignsCREB-Off = Fewer Depressive-like Signs

Forced Swim Test (FST)

SwimmingSwimming Immobile

Forced Swimming Activates CREB in the NAc

Ind

uct

ion

(sw

im /

no

sw

im)

CREB in the NAc normally plays a role in reacting to stressCREB in the NAc normally plays a role in reacting to stress

Pliakas et al., 2001

Biology & Behavior

DrugsDrugsStressStress

CREBCREBIn NAcIn NAc

DepressiveDepressiveBehaviorBehavior

CREB Target GenesCREB Target Genes

CREB (cAMP Response Element Binding Protein)

AMPA/GluR1Rs NMDARs

Gs Gi/o

G protein-coupled receptors

Ca2+

PKA

ATPcAMP

CaM

MAPK

RSK

CaMKIV

CREB

CREB

P

P

alteredgeneexpression

CREB

L-type Ca2+channels

TrkB

Neurotrophinreceptors

adenylate cyclase

Gq

PLC

CaMKII

PDE

TH BDNF

Dynorphin

Fos CRF

Overview

1. CREB

2. Functional role of CREB in the NAc

3. CREB and dynorphin

4. Kappa antagonists and agonists

DynorphinDynorphin

• • It has CRE sites in its promoter (Douglass et al., 1994)It has CRE sites in its promoter (Douglass et al., 1994)

• • It is regulated by drugs of abuse (Hurd and Herkenham,It is regulated by drugs of abuse (Hurd and Herkenham, 1993; Daunais et al., 1993; Cole et al., 1995)1993; Daunais et al., 1993; Cole et al., 1995)

• • Kappa agonists are aversive rats (Bals-Kubik et al., 1993)Kappa agonists are aversive rats (Bals-Kubik et al., 1993)

• • Kappa agonists are aversive in people (Pfeiffer et al.,Kappa agonists are aversive in people (Pfeiffer et al., 1986)1986)

• • It is a kappa opioid receptor ligand (Chavkin et al., 1982)It is a kappa opioid receptor ligand (Chavkin et al., 1982)

CREB Increases Dynorphin mRNAin the NAc

CREB-On =CREB-On =More DynorphinMore Dynorphin

CREB-Off =CREB-Off =Less DynorphinLess Dynorphin

Carlezon et al., 1998

Stress Increases Dynorphin mRNAin the NAc

Stress = More DynorphinStress = More Dynorphin

Chartoff et al., unpublished

.

0

0.5

1

1.5

2

2.5

mR

NA

(d

yno

rph

in/

-act

in)

Sham FST FST + DMI

**

Biology & Behavior

DrugsDrugsStressStress

CREBCREBIn NAcIn NAc

DepressiveDepressiveBehaviorsBehaviors

Biology & Behavior

DrugsDrugsStressStress

CREBCREBIn NAcIn NAc

DepressiveDepressiveBehaviorsBehaviors

dynorphindynorphin

Clinical ImplicationsClinical Implications

Overview

1. CREB

2. Functional role of CREB in the NAc

3. CREB and dynorphin

4. Kappa antagonists and agonists

U-69593 (kappa agonist) increases immobilityand decreases swimming

.

a U-69593 (mg/kg, IP) - FST b Locomotor Activity

10

20

30

40

10 mg/kg

3.0 mg/kg

1.0 mg/kg

0.3 mg/kg

0.1 mg/kg

acidic veh

0

**

*

immobility swimming climbing

Me

an

Co

un

ts

Me

an

Co

un

ts

**

*******

10 mg/kg

3.0 mg/kg

acidic veh

0

500

1000

1500

2000

2500

3000

**

Mague et al., 2003

ANTI (IP) decreases immobilityand increases climbing

.

a

10

20

30

40

3.0 mg/kg

1.0 mg/kg

0.3 mg/kg

0.1 mg/kg

water

0

***

ANTI (mg/kg, IP) - FST

immobility swimming climbing

b

0

500

1000

1500

2000

2500

30003.0 mgkg

water

Locomotor Activity

Me

an

Co

un

ts

Me

an

Co

un

ts

** *

**

Mague et al., 2003*ANTI: 5’-acetamidinoethylnaltrindole

Proposed Circuitry

Carlezon et al., 2000

Proposed Circuitry

Carlezon et al., 2000

X X

Proposed Circuitry

Carlezon et al., 2000

X X

O

O

OO

O

O

O

O

Salvinorin A(kappa agonist)

Kappa-selective agonist

(Roth et al., 2002 )

O

O

O

O O

O

O

O

Salvinorin A

Microdialysis (NAc)

.

0

25

50

75

100

125

150

% D o p a m i n e

-40 -20 0 20 40 60 80 100 120

Time (min)

SalvA 1.0

SalvA 0.125

DMSO

** ** ** ****

*

Dopaminea

.

Serotonin

0

25

50

75

100

125

150

-40 -20 0 20 40 60 80 100 120

Time (min)% S e r o t o n i n

b

(Carlezon et al., 2005)

Abuse Liability of Kappa Antagonists?

Effect of kappa ligands on ICSSEffect of kappa ligands on ICSS

Effect of kappa ligands on ICSSEffect of kappa ligands on ICSS

Effect of kappa ligands on ICSSEffect of kappa ligands on ICSS

Effect of kappa ligands on ICSSEffect of kappa ligands on ICSS

O

O

OO

O

O

O

O

Salvinorin A(kappa agonist)

Medicinal Chemistry Program

Furan-ring derivatives

Lactone-ring derivativesC2 derivatives

C4 derivatives

Does CREB in the NAc Regulate Mood?

Carlezon & Konradi, 2004Carlezon & Konradi, 2004

AcknowledgementsAcknowledgementsCarlezon LabCarlezon LabAndrea Pliakas

Andreas ArvanitogiannisRebecca Ralph-Williams

Sonia GuedicheSteve MagueBrian Gilliss

Elena ChartoffHilarie Tomasiewicz

Mark TodtenkopfEdward Meloni

Alexandra JacksonJacqueline Marcus

Maria PapadopoulouJennifer DiNieriKatie FamousAndrew Smith

Jessica PohlmanAram ParsegianMelissa Stoos

Lyle GeretyTracie PaineDost Ongur

Allison KnollMatthew Barhight

Antonia Dow

Funding SourcesNIDA, NIMH, NARSAD

McLean LabsBruce Cohen, Christine KonradiRachael Neve, Susan Andersen

Special AcknowledgementsSpecial Acknowledgements

Waletzky FamilyWaletzky Family

Society for NeuroscienceSociety for Neuroscience

Kappa Antagonists have Antidepressant EffectsT

ime

(se

c)

Be

am

Bre

aks

(1

hr)

Locomotor ActivityLatency to Immobility

CBP/p300

.

P

CR

EB

P

CR

EB

HAT

CRE

mC

RE

B

P

CR

EB

X

CBP/p300

RNAPol-II

CRE

RNAPol-II

A

““CREB-On”CREB-On”

““CREB-Off”CREB-Off”

O

O

OO

O

O

O

O

Salvinorin A(kappa agonist)

Kappa-selective agonist

Salvia Divinorum

FST

(Carlezon et al., JPET, in press)

O

O

O

O O

O

O

O

Salvinorin A

.

0

10

20

30

40

2.0

1.0

0.5

0.25

0.125

Vehicle

Me

an

Co

un

ts

immobility swimming climbing

a b

Dis

tan

ce T

rave

led

(cm

)

0

500

1000

1500

2000

********

******

ICSS

O

O

O

O O

O

O

O

Salvinorin A

.

80

100

120

140

Sal Veh 0.125 0.25 0.5 1.0 2.0 4.0

* ** **

Dose Salvinorin A (mg/kg, IP)

Per

cent

Bas

elin

e T

hres

hold

0

(Carlezon et al., JPET, in press)

O

O

O

O O

O

O

O

Salvinorin A

Microdialysis (NAc)

.

0

25

50

75

100

125

150

% D o p a m i n e

-40 -20 0 20 40 60 80 100 120

Time (min)

SalvA 1.0

SalvA 0.125

DMSO

** ** ** ****

*

Dopaminea

.

Serotonin

0

25

50

75

100

125

150

-40 -20 0 20 40 60 80 100 120

Time (min)% S e r o t o n i n

b

(Carlezon et al., JPET, in press)

Recommended